Cancer ▲ Genomics|Update|Current

Genomics|Update|Current

Cancer

BRAF mutation analysis is a valid tool to implement in Lynch syndrome diagnosis in patients classified according to the Bethesda guidelines 
Molinari F, et al. Tumori 2014 May-2014 Jun;100(3):315-20

Breast-cancer risk in families with mutations in PALB2
Antoniou AC, et al. New England Journal of Medicine2014 Aug 13

Study shows third gene as indicator for breast cancer, by Nicholas Bakalar, The New York Times, Aug 6

Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.
Gronwald J et al, Breast Cancer Res Treat. 2014 Jul;146(2):421-7.

Economic assesment of the routine use of Oncotype DX assay for early breast cancer in Franche-Comte region 
Nerich V, et al. Bull Cancer 2014 Aug;101(7-8):681-9

Exploring the cancer risk perception and interest in genetic services among Indigenous people in Queensland, Australia 
Bernardes CM, et al. Aust N Z J Public Health 2014 Aug;38(4):344-8

Fourfold increased detection of Lynch syndrome by raising age limit for tumour genetic testing from 50 to 70 years is cost-effective. 
Sie AS, et al. Ann Oncol. 2014 Jul 31

Knowledge and attitudes of oncology nurses regarding pharmacogenomic testing 
Dodson C Clin J Oncol Nurs 2014 Aug;18(4):E64-E70